γCD/HPγCD mixtures as solubilizer: Solid-state characterization and sample dexamethasone eye drop suspension

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 13, Issue 3, 2010, Pages 336-350

  Jansook, Phatsawee ^a   Ritthidej, Garnpimol C ^b   Ueda, Haruhisa ^c   Stefánsson, Einar ^d   Loftsson, Thorsteinn ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c HOSHI UNIVERSITY   (Japan)

^d LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL GAMMA CYCLODEXTRIN; DEXAMETHASONE; GAMMA CYCLODEXTRIN; POLOXAMER; POVIDONE; UNCLASSIFIED DRUG; EYE DROPS; GAMMA CYCLODEXTRIN DERIVATIVE; GAMMA-CYCLODEXTRIN; GLUCOCORTICOID; HYDROXYPROPYL GAMMA CYCLODEXTRIN; HYDROXYPROPYL-GAMMA-CYCLODEXTRIN;

ANIMAL TISSUE; ARTICLE; COMPLEX FORMATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG TRANSPORT; HYDRODYNAMICS; INFRARED SPECTROSCOPY; MEMBRANE TRANSPORT; NONHUMAN; PARTICLE SIZE; SCLERA; SOLID STATE; SUSPENSION; SWINE; X RAY DIFFRACTION; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; MICELLE; POSTERIOR EYE SEGMENT; SCANNING ELECTRON MICROSCOPY; SOLUBILITY;

ANIMALS; CALORIMETRY, DIFFERENTIAL SCANNING; DEXAMETHASONE; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; GAMMA-CYCLODEXTRINS; GLUCOCORTICOIDS; MICELLES; MICROSCOPY, ELECTRON, SCANNING; OPHTHALMIC SOLUTIONS; PARTICLE SIZE; POLOXAMER; POSTERIOR EYE SEGMENT; POVIDONE; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SUSPENSIONS; SWINE;

EID: 78650412127     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3m88b     Document Type: Article

References (48)

1. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Delivery Rev, 2007; 59:645-666.
2. Loftsson T, Duchene D. Cyclodextrins and their pharmaceutical applications. Int J Pharm, 2007; 329:1-11.
3. Loftsson T, Vogensen SB, Brewster ME, Konradsdottir F. Effects of cyclodextrins on drug delivery through biological membranes. J Pharm Sci, 2007; 96:2532-2546.
4. Luo LB, Chen HL, Wang F, Dai QP, Tang WX. Thermolysis of β-cyclodextrin/alkylcobaloxime inclusion complexes in the solid state. Thermochim Acta, 1997; 298:129-134.
5. Palmieri GF, Giovannucci G, Antonini I, Martelli S. Inclusion complexation of fenofibrate with β- cyclodextrin and hydroxypropyl- β-cyclodextrin. Evaluation of interactions in solution and solid complex characterization. STP Pharma Sci, 1997; 7:174-181.
6. Mielcarek J. Photochemical stability of the inclusion complexes of nicardipine with α-, γ-cyclodextrin, methyl-β-cyclodextrin and hydroxypropyl-β- cyclodextrin in the solid state and in solution. Pharmazie, 1996; 51:477-479.
7. Spulber M, Pinteala M, Fifere A, Harabagiu V, Simionescu BC. Inclusion complexes of 5- flucytosine with β-cyclodextrin and hydroxypropyl- β-cyclodextrin: characterization in aqueous solution and in solid state. J Inclusion Phenom Macrocyclic Chem, 2008; 62:117-125.
8. Amato ME, Lipkowitz KB, Lombardo GM, Pappalardo GC. NMR spectroscopic evidence and molecular dynamics studies on inclusion and noninclusion phenomena between β-cyclodextrin and new anti-Alzheimer's drugs tacrine (CI-970), velnacrine (HP-029) and suronacrine (HP-128). J Chem Soc., Perkin Trans, 1996; 2:321-325.
9. Duan MS, Zhao N, Ossurardottir IB, Thorsteinsson T, Loftsson T. Cyclodextrin solubilization of the antibacterial agents triclosan and triclocarban: Formation of aggregates and higher-order complexes. Int J Pharm, 2005; 297:213-222
10. Loftsson T, Masson M, Brewster ME. Selfassociation of cyclodextrins and cyclodextrin complexes. J Pharm Sci, 2004; 93:1091-1099.
11. He YF, Fu P, Shen XH, Gao HC. Cyclodextrinbased aggregates and characterization by microscopy. Micron, 2008; 39:495-516.
12. Jansook P, Kurkov SV, Loftsson T. Cyclodextrin as solubilizers: Formation of complex aggregates. J Pharm Sci, 2010; 99:719-729.
13. Loftsson T, Jarvinen T. Cyclodextrins in ophthalmic drug delivery. Adv Drug Delivery Rev, 1999; 36:59-79.
14. Loftsson T, Frioriksdottir H, Sigurdardottir AM, Ueda H. The effect of water-soluble polymers on drug-cyclodextrin complexation. Int J Pharm, 1994; 110:169-177.
15. Jarho P, Pate DW, Brenneisen R, Jarvinen T. Hydroxypropyl-β-cyclodextrin and its combination with hydroxypropyl-methylcellulose increases aqueous solubility of Δ(9)-tetrahydrocannabinol. Life Sci, 1998; 63: Pl381-Pl384.
16. Loftsson T, Frioriksdottir H. The effect of watersoluble polymers on the aqueous solubility and complexing abilities of β-cyclodextrin. Int J Pharm, 1998; 163:115-121.
17. Ribeiro LSS, Ferreira DC, Veiga FJB. Physicochemical investigation of the effects of water-soluble polymers on vinpocetine complexation with β-cyclodextrin and its sulfobutyl ether derivative in solution and solid state. Eur J Pharm Sci, 2003; 20:253-266.
18. Kaur IP, Smitha R, Aggarwal D, Kapil M. Acetazolamide: future perspective in topical glaucoma therapeutics. Int J Pharm, 2002; 248:1-14.
19. Cappello B, Carmignani C, Iervolino M, Immacolata La Rotonda M, Fabrizio Saettone M. Solubilization of tropicamide by hydroxypropyl-β- cyclodextrin and water-soluble polymers: in vitro/in vivo studies. Int J Pharm, 2001; 213:75-81.
20. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Delivery Rev, 2005; 57:1595-1639.
21. Ma WD, Xu H, Wang C, Nie SF, Pan WS. Pluronic F127-g-poly(acrylic acid) copolymers as in situ gelling vehicle for ophthalmic drug delivery system. Int J Pharm, 2008; 350:247-256.
22. El-Kamel AH. In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. Int J Pharm, 2002; 241:47-55.
23. Qi H, Li L, Huang C, Li W, Wu C. Optimization and physicochemical characterization of thermosensitive poloxamer gel containing puerarin for ophthalmic use. Chem Pharm Bull (Tokyo), 2006; 54:1500-1507.
24. Kim EY, Gao ZG, Park JS, Li H, Han K. rhEGF/HP-β-CD complex in poloxamer gel for ophthalmic delivery. Int J Pharm, 2002; 233:159-167.
25. Edsman K, Carlfors J, Petersson R. Rheological evaluation of poloxamer as an in situ gel for ophthalmic use. Eur J Pharm Sci, 1998; 6:105-112.
26. Bejjani RA, Behar-Cohen F, Benezra D, Gurny R, Delie F. Polymeric nanoparticles for drug delivery to the posterior segment of the eye. Chimia, 2005; 59:344-347.
27. Kim SH, Lutz RJ, Wang NS, Robinson MR. Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res, 2007; 39:244-254.
28. Loftsson T, Hreinsdottir D, Stefansson E. Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops. J Pharm Pharmacol, 2007; 59:629-635.
29. Sigurdsson HH, Konraethsdottir F, Loftsson T, Stefansson E. Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye. Acta Ophthalmol Scand, 2007; 85:598-602.
30. Sigurdsson HH, Stefansson E, Gudmundsdottir E, Eysteinsson T, Thorsteinsdottir M, Loftsson T. Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administration. J Control Release, 2005; 102:255-262.
31. Jansook P, Loftsson T. CDs as solubilizers: Effects of excipients and competing drugs. Int J Pharm, 2009; 379:32-40.
32. Jansook P, Loftsson T. γCD/HPγCD: Synergistic solubilization. Int J Pharm, 2008; 363:217-219.
33. Martin, A. Physical Pharmacy. 4th ed., Lippincott William an Wilkins, Baltimore, USA, pp 478-481, 2001.
34. Council of Europe. European Pharmacopoeia. 6th ed., Strasbourg, France, 2006.
35. Khan KA. Concept of dissolution efficiency. J Pharm Pharmaco, 1975; 27:48-49.
36. Ciba-Geigy., Wissenschaftliche Tabellen Geigy. 8th ed. Basel: Ciba-Geigy, 1977.
37. Cruysberg LP, Nuijts RM, Geroski DH, Koole LH, Hendrikse F, Edelhauser HF. In vitro human scleral permeability of fluorescein, dexamethasonefluorescein, methotrexate-fluorescein and rhodamine 6G and the use of a coated coil as a new drug delivery system. J Ocul Pharmacol Ther, 2002; 18:559-569.
38. Meier MM, Luiz MTB, Szpoganicz B, Soldi V. Thermal analysis behavior of β- and γ-cyclodextrin inclusion complexes with capric and caprilic acid. Thermochim Acta, 2001; 375:153-160.
39. Yilmaz VT, Karadag A, Icbudak H. Thermaldecomposition of β-cyclodextrin inclusion complexes of ferrocene and their derivatives. Thermochim Acta, 1995; 261:107-118.
40. Ribeiro L, Loftsson T, Ferreira D, Veiga F. Investigation and physicochemical characterization of vinpocetine-sulfobutyl ether β-cyclodextrin binary and ternary complexes. Chem Pharm Bull (Tokyo), 2003; 51:914-922.
41. Mathis GA. Clinical ophthalmic pharmacology and therapeutics: ocular drug delivery, In Gelatt KN (ed), Veterinary Ophthalmology. Lippincott Williams & Wilkins, Florida pp 291-297, 1999.
42. Arias JL, Lopez-Viota M, Clares B, Ruiz MA. Stability of fenbendazole suspensions for veterinary use Correlation between zeta potential and sedimentation. Eur J Pharm Sci, 2008; 34:257-262.
43. Kassem MA, Rahman AAA, Ghorab MM, Ahmed MB, Khalil RM. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm, 2007; 340:126-133.
44. Malaekeh-Nikouei B, Nassirli H, Davies N. Enhancement of cyclosporine aqueous solubility using α- and hydroxypropyl β-cyclodextrin mixtures. J Inclusion Phenom Macrocyclic Chem, 2007; 59: 245-250.
45. Kristinsson JK, Fridriksdottir H, Thorisdottir S, Sigurdardottir AM, Stefansson E, Loftsson T. Dexamethasone-cyclodextrin-polymer cocomplexes in aqueous eye drops - Aqueous humor pharmacokinetics in humans. Invest Ophthalmol Vis Sci, 1996; 37: 1199-1203.
46. Amrite AC, Edelhauser HF, Singh SR, Kompella UB. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis, 2008; 14:150-160.
47. Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv Drug Delivery Rev, 2001; 52:37-48.
48. Koevary SB. Pharmacokinetics of topical ocular drug delivery: Potential uses for the treatment of diseases of the posterior segment and beyond. Curr Drug Metab, 2003; 4:213-222.